A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen

Vaccine

Volumn 29, Issue 32, 2011, Pages 5294-5303

  Xiao, Sa ^a   Kumar, Manish ^a   Yang, Xiuli ^a   Akkoyunlu, Mustafa ^b   Collins, Peter L ^c   Samal, Siba K ^a   Pal, Utpal ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Borrelia burgdorferi; Immunization; Lyme disease; Newcastle disease virus; Vaccine

Indexed keywords

BACTERIAL PROTEIN; BASIC MEMBRANE PROTEIN A; OUTER SURFACE PROTEIN C; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL LOAD; BORRELIA BURGDORFERI; CHICKEN; CONTROLLED STUDY; FEMALE; HAMSTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION CONTROL; LYME DISEASE; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; CHICKENS; CRICETINAE; FEMALE; GENETIC VECTORS; IMMUNIZATION; LYME DISEASE; MICE; NEWCASTLE DISEASE VIRUS; POLYMERASE CHAIN REACTION;

EID: 79960329611     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.010     Document Type: Article

References (65)

1. Steward M., Vipond I.B., Millar N.S., Emmerson P.T. RNA editing in Newcastle disease virus. J Gen Virol 1993, 74(December (Pt 12)):2539-2547.
2. Lamb R.A., Parks G.D. Paramyxoviridae: the viruses and their replication. Fields virology 2007, 1449-1496. Lippincott Williams and Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
3. Bukreyev A., Collins P.L. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther 2008, 10(February (1)):46-55.
4. Krishnamurthy S., Huang Z., Samal S.K. Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation. Virology 2000, 278(December (1)):168-182.
5. DiNapoli J.M., Yang L., Suguitan A., Elankumaran S., Dorward D.W., Murphy B.R., et al. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J Virol 2007, 81(November (21)):11560-11568.
6. Huang Z., Elankumaran S., Panda A., Samal S.K. Recombinant Newcastle disease virus as a vaccine vector. Poult Sci 2003, 82(June (6)):899-906.
7. Schirrmacher V., Griesbach A., Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol 2001, 18(May (5)):945-952.
8. Vigil A., Martinez O., Chua M.A., Garcia-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 2008, 16(November (11)):1883-1890.
9. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010, 84(February (3)):1489-1503.
10. Bukreyev A., Huang Z., Yang L., Elankumaran S., St Claire M., Murphy B.R., et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol 2005, 79(November (21)):13275-13284.
11. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Cros J., Mertz S.E., Jewell N.A., et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 2006, 80(February (3)):1130-1139.
12. Nakaya Y., Nakaya T., Park M.S., Cros J., Imanishi J., Palese P., et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. J Virol 2004, 78(September (17)):9366-9375.
13. Carnero E., Li W., Borderia A.V., Moltedo B., Moran T., Garcia-Sastre A. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009, 83(January (2)):584-597.
14. DiNapoli J.M., Kotelkin A., Yang L., Elankumaran S., Murphy B.R., Samal S.K., et al. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A 2007, 104(June (23)):9788-9793.
15. Huang Z., Elankumaran S., Yunus A.S., Samal S.K. A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. J Virol 2004, 78(September (18)):10054-10063.
16. Khattar S.K., Collins P.L., Samal S.K. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010, 28(April (18)):3159-3170.
17. Kortekaas J., de Boer S.M., Kant J., Vloet R.P., Antonis A.F., Moormann R.J. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28(June (27)):4394-4401.
18. Borrelia, molecular biology, host interaction and pathogenesis 2010, Caister Academic Press, Norfolk, UK. D.S. Samuels, J.D. Radolf (Eds.).
19. Steere A.C., Coburn J., Glickstein L. The emergence of Lyme disease. J Clin Invest 2004, 113(April (8)):1093-1101.
20. Wang G., Aguero-Rosenfeld M.E., Wormser G.P., Schwartz I. Detection of Borrelia burgdorferi. Borrelia, molecular biology, host interaction and pathogenesis 2010, 443-466. Caister Academic Press, Norfolk, UK. D.S. Samuels, J.D. Radolf (Eds.).
21. Fikrig E., Barthold S.W., Kantor F.S., Flavell R.A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990, 250:553-556.
22. Sigal L.H., Zahradnik J.M., Lavin P., Patella S.J., Bryant G., Haselby R., et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998, 339(4):216-222.
23. Steere A.C., Sikand V.K., Meurice F., Parenti D.L., Fikrig E., Schoen R.T., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998, 339(4):209-215.
24. Luke C.J., Carner K., Liang X., Barbour A.G. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 1997, 175(January (1)):91-97.
25. Gipson C.L., Davis N.L., Johnston R.E., de Silva A.M. Evaluation of venezuelan equine encephalitis (VEE) replicon-based outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease. Vaccine 2003, 21(September (25-26)):3875-3884.
26. Scheckelhoff M.R., Telford S.R., Hu L.T. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 2006, 24(March (11)):1949-1957.
27. Marconi R.T., Earnhart C.G. Lyme disease vaccines. Borrelia, molecular biology, host interaction and pathogenesis 2010, 461-480. Caister Academic Press, Norfolk, UK. D.S. Samuels, J.D. Radolf (Eds.).
28. Barthold S.W., Diego C., Philipp M.T. Animal models of borreliosis. Borrelia, molecular biology, host interaction and pathogenesis 2010, 353-405. Caister Academic Press, Norfolk, UK. D.S. Samuels, J.D. Radolf (Eds.).
29. Barthold S.W., Beck D.S., Hansen G.M., Terwilliger G.A., Moody K.D. Lyme borreliosis in selected strains and ages of laboratory mice. J Infect Dis 1990, 162:133-138.
30. Johnson R.C., Marek N., Kodner C. Infection of Syrian hamsters with Lyme disease spirochetes. J Clin Microbiol 1984, 20(December (6)):1099-1101.
31. Johnson R.C., Kodner C., Russell M., Duray P.H. Experimental infection of the hamster with Borrelia burgdorferi. Ann N Y Acad Sci 1988, 539:258-263.
32. Weis J.J., Bockenstedt L.K. Host response. Borrelia, molecular biology, host interaction and pathogenesis 2010, 413-441. Caister Academic Press, Norfolk, UK. D.S. Samuels, J.D. Radolf (Eds.).
33. Connolly S.E., Benach J.L. The versatile roles of antibodies in Borrelia infections. Nat Rev Microbiol 2005, 3(May (5)):411-420.
34. Bryksin A.V., Godfrey H.P., Carbonaro C.A., Wormser G.P., Aguero-Rosenfeld M.E., Cabello F.C. Borrelia burgdorferi BmpA, BmpB, and BmpD proteins are expressed in human infection and contribute to P39 immunoblot reactivity in patients with Lyme disease. Clin Diagn Lab Immunol 2005, 12(August (8)):935-940.
35. Liang F.T., Jacobs M.B., Bowers L.C., Philipp M.T. An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. J Exp Med 2002, 195(4):415-422.
36. Pal U., Wang P., Bao F., Yang X., Samanta S., Schoen R., et al. Borrelia burgdorferi basic membrane proteins A and B participate in the genesis of Lyme arthritis. J Exp Med 2008, 205(January (1)):133-141.
37. Schwan T.G., Piesman J., Golde W.T., Dolan M.C., Rosa P.A. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc Natl Acad Sci U S A 1995, 92(7):2909-2913.
38. Mathiesen M.J., Christiansen M., Hansen K., Holm A., Asbrink E., Theisen M. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J Clin Microbiol 1998, 36(December (12)):3474-3479.
39. Roessler D., Hauser U., Wilske B. Heterogeneity of BmpA (P39) among European isolates of Borrelia burgdorferi sensu lato and influence of interspecies variability on serodiagnosis. J Clin Microbiol 1997, 35(November (11)):2752-2758.
40. Bockenstedt L.K., Hodzic E., Feng S., Bourrel K.W., de Silva A., Montgomery R.R., et al. Borrelia burgdorferi strain-specific Osp C-mediated immunity in mice. Infect Immun 1997, 65(November (11)):4661-4667.
41. Gilmore R.D., Kappel K.J., Dolan M.C., Burkot T.R., Johnson B.J. Outer surface protein C (OspC), but not P39, is a protective immunogen against a tick-transmitted Borrelia burgdorferi challenge: evidence for a conformational protective epitope in OspC. Infect Immun 1996, 64(June (6)):2234-2239.
42. Probert W.S., Lefebvre R.B. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB or OspC but not OspD or the 83-kilodalton antigen. Infect Immun 1994, 62:1920-1926.
43. Schloer G.M., Hanson R.P. Relationship of plaque size and virulence for chickens of 14 representative Newcastle disease virus strains. J Virol 1968, 2(January (1)):40-47.
44. Elias A.F., Stewart P.E., Grimm D., Caimano M.J., Eggers C.H., Tilly K., et al. Clonal polymorphism of Borrelia burgdorferi strain B31 MI: implications for mutagenesis in an infectious strain background. Infect Immun 2002, 70(April (4)):2139-2150.
45. DiNapoli J.M., Ward J.M., Cheng L., Yang L., Elankumaran S., Murphy B.R., et al. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 2009, 27(March (10)):1530-1539.
46. Kolakofsky D., Pelet T., Garcin D., Hausmann S., Curran J., Roux L., et al. synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 1998, 72(February (2)):891-899.
47. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987, 15(October (20)):8125-8148.
48. Huang Z., Krishnamurthy S., Panda A., Samal S.K. High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J Gen Virol 2001, 82(July (Pt 7)):1729-1736.
49. Iorio R.M., Syddall R.J., Sheehan J.P., Bratt M.A., Glickman R.L., Riel A.M. Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition. J Virol 1991, 65(September (9)):4999-5006.
50. Pal U., Yang X., Chen M., Bockenstedt L.K., Anderson J.F., Flavell R.A., et al. OspC facilitates Borrelia burgdorferi invasion of Ixodes scapularis salivary glands. J Clin Invest 2004, 113(January (2)):220-230.
51. Yang X., Coleman A.S., Anguita J., Pal U. A chromosomally encoded virulence factor protects the Lyme disease pathogen against host-adaptive immunity. PLoS Pathog 2009, 5(March (3)):e1000326.
52. Johnson R.C., Kodner C., Russell M., Duray P.H. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 1986, 54:897.
53. Allan W.H., Gough R.E. A standard haemagglutination inhibition test for Newcastle disease (1). A comparison of macro and micro methods. Vet Rec 1974, 95(August (6)):120-123.
54. Nelson C.B., Pomeroy B.S., Schrall K., Park W.E., Lindeman R.J. An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health 1952, 42(June (6)):672-678.
55. Lovrich S.D., La Fleur R.L., Jobe D.A., Johnson J.C., Asp K.E., Schell R.F., et al. Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease. Clin Vaccine Immunol 2007, 14(May (5)):635-637.
56. Lovrich S.D., Jobe D.A., Schell R.F., Callister S.M. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Clin Diagn Lab Immunol 2005, 12(June (6)):746-751.
57. Liang F.T., Brown E.L., Wang T., Iozzo R.V., Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol 2004, 165(September (3)):977-985.
58. Rudd P.M., Elliott T., Cresswell P., Wilson I.A., Dwek R.A. Glycosylation and the immune system. Science 2001, 291(March (5512)):2370-2376.
59. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 50(March (Suppl. 2)):S54-S65.
60. Roehrig J.T., Piesman J., Hunt A.R., Keen M.G., Happ C.M., Johnson B.J. The hamster immune response to tick-transmitted Borrelia burgdorferi differs from the response to needle-inoculated, cultured organisms. J Immunol 1992, 149(December (11)):3648-3653.
61. Dubska L., Literak I., Kocianova E., Taragelova V., Sverakova V., Sychra O., et al. The importance of synanthropic wild birds in distribution of Borrelia spirochetes: analysis of spring collections of Ixodes ricinus ticks feeding on passerine birds in the Czech Republic. Appl Environ Microbiol 2010, (December).
62. Dubska L., Literak I., Kocianova E., Taragelova V., Sychra O. Differential role of passerine birds in distribution of Borrelia spirochetes, based on data from ticks collected from birds during the postbreeding migration period in Central Europe. Appl Environ Microbiol 2009, 75(February (3)):596-602.
63. Comstedt P., Bergstrom S., Olsen B., Garpmo U., Marjavaara L., Mejlon H., et al. Migratory passerine birds as reservoirs of Lyme borreliosis in Europe. Emerg Infect Dis 2006, 12(July (7)):1087-1095.
64. Taragel'ova V., Koci J., Hanincova K., Kurtenbach K., Derdakova M., Ogden N.H., et al. Blackbirds and song thrushes constitute a key reservoir of Borrelia garinii, the causative agent of borreliosis in Central Europe. Appl Environ Microbiol 2008, 74(February (4)):1289-1293.
65. Hanincova K., Taragelova V., Koci J., Schafer S.M., Hails R., Ullmann A.J., et al. Association of Borrelia garinii and B. valaisiana with songbirds in Slovakia. Appl Environ Microbiol 2003, 69(May (5)):2825-2830.